Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-01-2019 | Review

The downside of antimicrobial agents for wound healing

Authors: Apirujee Punjataewakupt, Supamas Napavichayanun, Pornanong Aramwit

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 1/2019

Abstract

The use of topical antimicrobials is beneficial for infection control in wound care because wound infection is the major cause of delayed healing. The advantages of topical over systemic antimicrobials include a higher concentration at the target site, fewer systemic adverse effects, and a lower incidence of antimicrobial resistance. Nowadays, topical antimicrobials are divided into three groups: disinfectants, antiseptics, and antibiotics. Only antiseptics and antibiotics can be applied to living skin; therefore, this review will focus only on these groups. The advantages of each topical antimicrobial are well established; however, their disadvantages remain prominent. It is widely known that antiseptics show higher cytotoxicity and a broader spectrum of activity than antibiotics, whereas antibiotics show a higher probability of bacterial resistance development. However, there are still many adverse effects, resulting from each topical antimicrobial. This review aims to summarize the possible adverse effects of commonly used antiseptics (biguanide, silver, iodine, chlorine compounds, and other antiseptics), antibiotics (bacitracin, mafenide, mupirocin, neomycin, and silver sulfadiazine), and natural antimicrobials (curcumin and honey). Moreover, the antimicrobials that should be avoided in particular populations are also summarized in this review in order to increase awareness for antimicrobial selection in those populations.

Guest JF, Ayoub N, McIlwraith T, Uchegbu I, Gerrish A, Weidlich D, Vowden K, Vowden P (2015) Health economic burden that wounds impose on the National Health Service in the UK. BMJ Open 5(12):e009283. https://doi.org/10.1136/bmjopen-2015-009283 CrossRefPubMedPubMedCentral

Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK, Gottrup F, Gurtner GC, Longaker MT (2009) Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen 17(6):763–771. https://doi.org/10.1111/j.1524-475X.2009.00547.x CrossRefPubMedPubMedCentral

Gottrup F, Apelqvist J, Bjarnsholt T, Cooper R, Moore Z, Peters EJ, Probst S (2013) EWMA document: antimicrobials and non-healing wounds. Evidence, controversies and suggestions. J Wound Care 22(5 Suppl):S1–S89. https://doi.org/10.12968/jowc.2013.22.Sup5.S1 CrossRefPubMed

Vermeulen H, Westerbos SJ, Ubbink DT (2010) Benefit and harm of iodine in wound care: a systematic review. J Hosp Infect 76(3):191–199. https://doi.org/10.1016/j.jhin.2010.04.026 CrossRefPubMed

Lipsky BA, Hoey C (2009) Topical antimicrobial therapy for treating chronic wounds. Clin Infect Dis 49(10):1541–1549. https://doi.org/10.1086/644732 CrossRefPubMed

Thomas GW, Rael LT, Bar-Or R, Shimonkevitz R, Mains CW, Slone DS, Craun ML, Bar-Or D (2009) Mechanisms of delayed wound healing by commonly used antiseptics. J Trauma 66(1):82–90; discussion 90-81. https://doi.org/10.1097/TA.0b013e31818b146d CrossRef

Lio PA, Kaye ET (2009) Topical antibacterial agents. Infect Dis Clin N Am 23(4):945–963. https://doi.org/10.1016/j.idc.2009.06.006 CrossRef

Atiyeh BS, Dibo SA, Hayek SN (2009) Wound cleansing, topical antiseptics and wound healing. Int Wound J 6(6):420–430. https://doi.org/10.1111/j.1742-481X.2009.00639.x CrossRef

Dumville JC, Lipsky BA, Hoey C, Cruciani M, Fiscon M, Xia J (2017) Topical antimicrobial agents for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev 6:Cd011038. https://doi.org/10.1002/14651858.CD011038.pub2 CrossRefPubMed

10.

Chlorhexidine (2016) In: Aronson JK (ed) Meyler’s side effects of drugs, Sixteenth edn. Elsevier, Oxford, pp 239–248. https://doi.org/10.1016/B978-0-444-53717-1.00474-1 CrossRef

11.

Karpinski TM, Szkaradkiewicz AK (2015) Chlorhexidine--pharmaco-biological activity and application. Eur Rev Med Pharmacol Sci 19(7):1321–1326

12.

Giannelli M, Chellini F, Margheri M, Tonelli P, Tani A (2008) Effect of chlorhexidine digluconate on different cell types: a molecular and ultrastructural investigation. Toxicol in Vitro 22(2):308–317. https://doi.org/10.1016/j.tiv.2007.09.012 CrossRefPubMed

13.

Hidalgo E, Dominguez C (2001) Mechanisms underlying chlorhexidine-induced cytotoxicity. Toxicol in Vitro 15(4–5):271–276CrossRef

14.

Faria G, Cardoso CR, Larson RE, Silva JS, Rossi MA (2009) Chlorhexidine-induced apoptosis or necrosis in L929 fibroblasts: a role for endoplasmic reticulum stress. Toxicol Appl Pharmacol 234(2):256–265. https://doi.org/10.1016/j.taap.2008.10.012 CrossRefPubMed

15.

Li YC, Kuan YH, Lee SS, Huang FM, Chang YC (2014) Cytotoxicity and genotoxicity of chlorhexidine on macrophages in vitro. Environ Toxicol 29(4):452–458. https://doi.org/10.1002/tox.21771 CrossRefPubMed

16.

Voros P, Dobrindt O, Perka C, Windisch C, Matziolis G, Rohner E (2014) Human osteoblast damage after antiseptic treatment. Int Orthop 38(1):177–182. https://doi.org/10.1007/s00264-013-2107-y CrossRefPubMed

17.

Best AJ, Nixon MF, Taylor GJS (2007) Brief exposure of 0.05% chlorhexidine does not impair non-osteoarthritic human cartilage metabolism. J Hosp Infect 67(1):67–71. https://doi.org/10.1016/j.jhin.2007.05.014 CrossRefPubMed

18.

Krautheim AB, Jermann TH, Bircher AJ (2004) Chlorhexidine anaphylaxis: case report and review of the literature. Contact Dermat 50(3):113–116. https://doi.org/10.1111/j.0105-1873.2004.00308.x CrossRef

19.

Karpanen TJ, Worthington T, Conway BR, Hilton AC, Elliott TSJ, Lambert PA (2008) Penetration of chlorhexidine into human skin. Antimicrob Agents Chemother 52(10):3633–3636. https://doi.org/10.1128/AAC.00637-08 CrossRefPubMedPubMedCentral

20.

Case DE, McAinsh J, Rushton A, Winrow MJ (1976) Chlorhexidine: attempts to detect percutaneous absorption in man. In: Williams JD, Geddes AM (eds) Special problems in chemotherapy. Springer US, Boston, pp 367–374. https://doi.org/10.1007/978-1-4684-3120-9_57 CrossRef

21.

Nonami K, Saitoh S, Nishimura-Danjobara Y, Ishida S, Oyama Y (2016) Chlorhexidine possesses unique cytotoxic actions in rat thymic lymphocytes: its relation with electrochemical property of membranes. Environ Toxicol Pharmacol 48:17–21. https://doi.org/10.1016/j.etap.2016.09.024 CrossRefPubMed

22.

Creppy EE, Diallo A, Moukha S, Eklu-Gadegbeku C, Cros D (2014) Study of epigenetic properties of Poly(HexaMethylene Biguanide) hydrochloride (PHMB). Int J Environ Res Public Health 11(8):8069–8092. https://doi.org/10.3390/ijerph110808069 CrossRefPubMedPubMedCentral

23.

Röhner E, Hoff P, Winkler T, von Roth P, Seeger JB, Perka C, Matziolis G (2011) Polyhexanide and hydrogen peroxide inhibit proteoglycan synthesis of human chondrocytes. J Histotechnol 34(1):35–39. https://doi.org/10.1179/014788811X12949268296121 CrossRefPubMedPubMedCentral

24.

Muller G, Kramer A (2008) Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial activity and cellular cytotoxicity. J Antimicrob Chemother 61(6):1281–1287. https://doi.org/10.1093/jac/dkn125 CrossRefPubMed

25.

Kramer A, Roth B, Muller G, Rudolph P, Klocker N (2004) Influence of the antiseptic agents polyhexanide and octenidine on FL cells and on healing of experimental superficial aseptic wounds in piglets. A double-blind, randomised, stratified, controlled, parallel-group study. Skin Pharmacol Physiol 17(3):141–146. https://doi.org/10.1159/000077241 CrossRefPubMed

26.

Röhner E, Seeger JB, Hoff P, Dahn-Wollenberg S, Perka C, Matziolis G (2011) Toxicity of polyhexanide and hydrogen peroxide on human chondrocytes in vitro. Orthopedics 34(7):e290–e294. https://doi.org/10.3928/01477447-20110526-02 CrossRefPubMed

27.

Ince A, Schutze N, Hendrich C, Jakob F, Eulert J, Lohr JF (2007) Effect of polyhexanide and gentamycin on human osteoblasts and endothelial cells. Swiss Med Wkly 137(9–10):139–145 https://doi.org/2007/09/smw-11434 PubMed

28.

Yabes JM, White BK, Murray CK, Sanchez CJ, Mende K, Beckius ML, Zera WC, Wenke JC, Akers KS (2016) In vitro activity of manuka honey and polyhexamethylene biguanide on filamentous fungi and toxicity to human cell lines. Med Mycol. https://doi.org/10.1093/mmy/myw070

29.

Hubner NO, Kramer A (2010) Review on the efficacy, safety and clinical applications of polihexanide, a modern wound antiseptic. Skin Pharmacol Physiol 23(Suppl):17–27. https://doi.org/10.1159/000318264 CrossRefPubMed

30.

Röhner E, Kolar P, Seeger JB, Arnholdt J, Thiele K, Perka C, Matziolis G (2011) Toxicity of antiseptics against chondrocytes: what is best for the cartilage in septic joint surgery? Int Orthop 35(11):1719–1723. https://doi.org/10.1007/s00264-010-1178-2 CrossRefPubMedPubMedCentral

31.

Polyhexanide (2016) In: Aronson JK (ed) Meyler’s side effects of drugs, Sixteenth edn. Elsevier, Oxford, p 859. https://doi.org/10.1016/B978-0-444-53717-1.01315-9 CrossRef

32.

Kautz O, Schumann H, Degerbeck F, Venemalm L, Jakob T (2010) Severe anaphylaxis to the antiseptic polyhexanide. Allergy 65(8):1068–1070. https://doi.org/10.1111/j.1398-9995.2009.02299.x CrossRefPubMed

33.

Klasen HJ (2000) Historical review of the use of silver in the treatment of burns. I. Early uses. Burns 26(2):117–130CrossRef

34.

Atiyeh BS, Costagliola M, Hayek SN, Dibo SA (2007) Effect of silver on burn wound infection control and healing: review of the literature. Burns 33(2):139–148. https://doi.org/10.1016/j.burns.2006.06.010 CrossRef

35.

Hidalgo E, Dominguez C (1998) Study of cytotoxicity mechanisms of silver nitrate in human dermal fibroblasts. Toxicol Lett 98(3):169–179CrossRef

36.

Poon VK, Burd A (2004) In vitro cytotoxity of silver: implication for clinical wound care. Burns 30(2):140–147. https://doi.org/10.1016/j.burns.2003.09.030 CrossRefPubMed

37.

Fuller FW (2009) The side effects of silver sulfadiazine. J Burn Care Res 30(3):464–470. https://doi.org/10.1097/BCR.0b013e3181a28c9b CrossRef

38.

Lansdown AB (2010) A pharmacological and toxicological profile of silver as an antimicrobial agent in medical devices. Adv Pharmacol Sci 2010:910686. https://doi.org/10.1155/2010/910686

39.

Sterling JP (2014) Silver-resistance, allergy, and blue skin: truth or urban legend? Burns 40. Supplement 1:S19–S23. https://doi.org/10.1016/j.burns.2014.10.007 CrossRef

40.

Chou T-D, Gibran NS, Urdahl K, Lin EY, Heimbach DM, Engrav LH (1999) Methemoglobinemia secondary to topical silver nitrate therapy-a case report. Burns 25(6):549–552. https://doi.org/10.1016/S0305-4179(99)00031-5 CrossRefPubMed

41.

McShan D, Ray PC, Yu H (2014) Molecular toxicity mechanism of nanosilver. J Food Drug Anal 22(1):116–127. https://doi.org/10.1016/j.jfda.2014.01.010 CrossRefPubMedPubMedCentral

42.

Riaz Ahmed KB, Nagy AM, Brown RP, Zhang Q, Malghan SG, Goering PL (2017) Silver nanoparticles: significance of physicochemical properties and assay interference on the interpretation of in vitro cytotoxicity studies. Toxicol in Vitro 38:179–192. https://doi.org/10.1016/j.tiv.2016.10.012 CrossRefPubMed

43.

AshaRani PV, Low Kah Mun G, Hande MP, Valiyaveettil S (2009) Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano 3(2):279–290. https://doi.org/10.1021/nn800596w CrossRefPubMed

44.

Szmyd R, Goralczyk AG, Skalniak L, Cierniak A, Lipert B, Filon FL, Crosera M, Borowczyk J, Laczna E, Drukala J, Klein A, Jura J (2013) Effect of silver nanoparticles on human primary keratinocytes. Biol Chem 394(1):113–123. https://doi.org/10.1515/hsz-2012-0202 CrossRefPubMed

45.

Burd A, Kwok CH, Hung SC, Chan HS, Gu H, Lam WK, Huang L (2007) A comparative study of the cytotoxicity of silver-based dressings in monolayer cell, tissue explant, and animal models. Wound Repair Regen 15(1):94–104. https://doi.org/10.1111/j.1524-475X.2006.00190.x CrossRefPubMed

46.

Larese FF, D’Agostin F, Crosera M, Adami G, Renzi N, Bovenzi M, Maina G (2009) Human skin penetration of silver nanoparticles through intact and damaged skin. Toxicology 255(1):33–37. https://doi.org/10.1016/j.tox.2008.09.025 CrossRefPubMed

47.

Brandt O, Mildner M, Egger AE, Groessl M, Rix U, Posch M, Keppler BK, Strupp C, Mueller B, Stingl G (2012) Nanoscalic silver possesses broad-spectrum antimicrobial activities and exhibits fewer toxicological side effects than silver sulfadiazine. Nanomedicine 8(4):478–488. https://doi.org/10.1016/j.nano.2011.07.005 CrossRefPubMed

48.

Vlachou E, Chipp E, Shale E, Wilson YT, Papini R, Moiemen NS (2007) The safety of nanocrystalline silver dressings on burns: a study of systemic silver absorption. Burns 33(8):979–985. https://doi.org/10.1016/j.burns.2007.07.014 CrossRefPubMed

49.

Trop M, Novak M, Rodl S, Hellbom B, Kroell W, Goessler W (2006) Silver-coated dressing acticoat caused raised liver enzymes and argyria-like symptoms in burn patient. J Trauma 60(3):648–652. https://doi.org/10.1097/01.ta.0000208126.22089.b6 CrossRefPubMed

50.

Zamora JL (1986) Chemical and microbiologic characteristics and toxicity of povidone-iodine solutions. Am J Surg 151(3):400–406. https://doi.org/10.1016/0002-9610(86)90477-0 CrossRefPubMed

51.

Kramer SA (1999) Effect of povidone-iodine on wound healing: a review. J Vasc Nurs 17(1):17–23CrossRef

52.

Balin AK, Pratt L (2002) Dilute povidone-iodine solutions inhibit human skin fibroblast growth. Dermatol Surg 28(3):210–214PubMed

53.

Sato S, Miyake M, Hazama A, Omori K (2014) Povidone-iodine-induced cell death in cultured human epithelial HeLa cells and rat oral mucosal tissue. Drug Chem Toxicol 37(3):268–275. https://doi.org/10.3109/01480545.2013.846364 CrossRefPubMed

54.

Polyvidone (povidone) iodine (2016) In: Aronson JK (ed) Meyler’s side effects of drugs (Sixteenth Edition). Elsevier, Oxford, pp 875–882. https://doi.org/10.1016/B978-0-444-53717-1.01320-2

55.

Leung AM, Braverman LE (2014) Consequences of excess iodine. Nat Rev Endocrinol 10(3):136–142. https://doi.org/10.1038/nrendo.2013.251 CrossRef

56.

Burgi H (2010) Iodine excess. Best Pract Res Clin Endocrinol Metab 24(1):107–115. https://doi.org/10.1016/j.beem.2009.08.010 CrossRef

57.

Perrin T, Hemett OM, Menth M, Descombes E (2012) Contrast-induced acute kidney injury following iodine opacification other than by intravascular injection. Clin Kidney J 5(5):456–458. https://doi.org/10.1093/ckj/sfs102 CrossRefPubMedPubMedCentral

58.

Cooper RA (2007) Iodine revisited. Int Wound J 4(2):124–137. https://doi.org/10.1111/j.1742-481X.2007.00314.x CrossRefPubMed

59.

Noda Y, Fujii K, Fujii S (2009) Critical evaluation of cadexomer-iodine ointment and povidone-iodine sugar ointment. Int J Pharm 372(1–2):85–90. https://doi.org/10.1016/j.ijpharm.2009.01.007 CrossRefPubMed

60.

Zhou LH, Nahm WK, Badiavas E, Yufit T, Falanga V (2002) Slow release iodine preparation and wound healing: in vitro effects consistent with lack of in vivo toxicity in human chronic wounds. Br J Dermatol 146(3):365–374CrossRef

61.

Laudanska H, Gustavson B (1988) In-patient treatment of chronic varicose venous ulcers. A randomized trial of cadexomer iodine versus standard dressings. J Int Med Res 16(6):428–435CrossRef

62.

Ohtani T, Mizuashi M, Ito Y, Aiba S (2007) Cadexomer as well as cadexomer iodine induces the production of proinflammatory cytokines and vascular endothelial growth factor by human macrophages. Exp Dermatol 16(4):318–323. https://doi.org/10.1111/j.1600-0625.2006.00532.x CrossRefPubMed

63.

Skog E, Arnesjo B, Troeng T, Gjores JE, Bergljung L, Gundersen J, Hallbook T, Hessman Y, Hillstrom L, Mansson T, Eilard U, Ekloff B, Plate G, Norgren L (1983) A randomized trial comparing cadexomer iodine and standard treatment in the out-patient management of chronic venous ulcers. Br J Dermatol 109(1):77–83CrossRef

64.

Bianchi J (2001) Cadexomer-iodine in the treatment of venous leg ulcers: what is the evidence? J Wound Care 10(6):225–229. https://doi.org/10.12968/jowc.2001.10.6.26085 CrossRefPubMed

65.

Holloway GA Jr, Johansen KH, Barnes RW, Pierce GE (1989) Multicenter trial of cadexomer iodine to treat venous stasis ulcer. West J Med 151(1):35–38PubMedPubMedCentral

66.

Murdoch R, Lagan KM (2013) The role of povidone and cadexomer iodine in the management of acute and chronic wounds. Phys Ther Rev 18(3):207–216. https://doi.org/10.1179/1743288X13Y.0000000082 CrossRef

67.

Dakin HD (1915) On the use of certain antiseptic substances in the treatment of infected wounds. Br Med J 2(2852):318–320CrossRef

68.

Ponzano GP (2007) Sodium hypochlorite: history, properties, electrochemical production. Contrib Nephrol 154:7–23. https://doi.org/10.1159/000096810

69.

Cardile AP, Sanchez CJ Jr, Hardy SK, Romano DR, Hurtgen BJ, Wenke JC, Murray CK, Akers KS (2014) Dakin solution alters macrophage viability and function. J Surg Res 192(2):692–699. https://doi.org/10.1016/j.jss.2014.07.019 CrossRefPubMed

70.

Hidalgo E, Bartolome R, Dominguez C (2002) Cytotoxicity mechanisms of sodium hypochlorite in cultured human dermal fibroblasts and its bactericidal effectiveness. Chem Biol Interact 139(3):265–282. https://doi.org/10.1016/S0009-2797(02)00003-0 CrossRefPubMed

71.

Peck B, Workeneh B, Kadikoy H, Patel SJ, Abdellatif A (2011) Spectrum of sodium hypochlorite toxicity in man—also a concern for nephrologists. NDT Plus 4(4):231–235. https://doi.org/10.1093/ndtplus/sfr053 CrossRefPubMedPubMedCentral

72.

Kozol RA, Gillies C, Elgebaly SA (1988) Effects of sodium hypochlorite (Dakin’s solution) on cells of the wound module. Arch Surg 123(4):420–423CrossRef

73.

Heggers JP, Sazy JA, Stenberg BD, Strock LL, McCauley RL, Herndon DN, Robson MC (1991) Bactericidal and wound-healing properties of sodium hypochlorite solutions: the 1991 Lindberg Award. J Burn Care Rehabil 12(5):420–424CrossRef

74.

Bruch MK (2007) Toxicity and safety of topical sodium hypochlorite. Contrib Nephrol 154:24–38. https://doi.org/10.1159/000096812 CrossRefPubMed

75.

Sood A, Granick MS, Tomaselli NL (2014) Wound dressings and comparative effectiveness data. Adv Wound Care 3(8):511–529. https://doi.org/10.1089/wound.2012.0401 CrossRef

76.

Loo AEK, Halliwell B (2012) Effects of hydrogen peroxide in a keratinocyte-fibroblast co-culture model of wound healing. Biochem Biophys Res Commun 423(2):253–258. https://doi.org/10.1016/j.bbrc.2012.05.100 CrossRefPubMed

77.

Watt BE, Proudfoot AT, Vale JA (2004) Hydrogen peroxide poisoning. Toxicol Rev 23(1):51–57CrossRef

78.

Bryan N, Ahswin H, Smart N, Bayon Y, Wohlert S, Hunt JA (2012) Reactive oxygen species (ROS)--a family of fate deciding molecules pivotal in constructive inflammation and wound healing. Eur Cell Mater 24:249–265CrossRef

79.

Loo AEK, Wong YT, Ho R, Wasser M, Du T, Ng WT, Halliwell B (2012) Effects of hydrogen peroxide on wound healing in mice in relation to oxidative damage. PLoS One 7(11):e49215. https://doi.org/10.1371/journal.pone.0049215 CrossRefPubMedPubMedCentral

80.

Hoffmann ME, Meneghini R (1979) Action of hydrogen peroxide on human fibroblast in culture. Photochem Photobiol 30(1):151–155. https://doi.org/10.1111/j.1751-1097.1979.tb07128.x CrossRefPubMed

81.

Vessey DA, Lee K-H, Blacker KL (1992) Characterization of the oxidative stress initiated in cultured human keratinocytes by treatment with peroxides. J Invest Dermatol 99(6):859–863. https://doi.org/10.1111/1523-1747.ep12614831 CrossRefPubMed

82.

Hydrogen peroxide (2010) In: Greim H (ed) The MAK-collection for occupational health and safety: MAK Value Documentations, vol 26. Wiley, Weinheim, pp 192–214. https://doi.org/10.1002/3527600418.mb772284e0026

83.

Howard B (2007) Bacitracin. In: Enna SJ, Bylund DB (eds) xPharm: the comprehensive pharmacology reference. Elsevier, New York, pp 1–4. https://doi.org/10.1016/B978-008055232-3.61280-2

84.

Held JL, Kalb RE, Ruszkowski AM, DeLeo V (1987) Allergic contact dermatitis from bacitracin. J Am Acad Dermatol 17(4):592–594. https://doi.org/10.1016/S0190-9622(87)70241-2 CrossRefPubMed

85.

Katz BE, Fisher AA (1987) Bacitracin: a unique topical antibiotic sensitizer. J Am Acad Dermatol 17(6):1016–1024. https://doi.org/10.1016/S0190-9622(87)70292-8 CrossRefPubMed

86.

Jacob SE, James WD (2004) From road rash to top allergen in a flash: bacitracin. Dermatol Surg 30(4 Pt 1):521–524. https://doi.org/10.1111/j.1524-4725.2004.30168.x CrossRefPubMed

87.

Schechter JF, Wilkinson RD, Carpio J (1984) Anaphylaxis following the use of bacitracin ointment: report of a case and review of the literature. Arch Dermatol 120(7):909–911. https://doi.org/10.1001/archderm.1984.01650430095017 CrossRefPubMed

88.

Cronin H, Mowad C (2009) Anaphylactic reaction to bacitracin ointment. Cutis 83(3):127–129PubMed

89.

Bacitracin (2016) In: Aronson JK (ed) Meyler’s side effects of drugs (Sixteenth Edition). Elsevier, Oxford, pp 807–808. https://doi.org/10.1016/B978-0-444-53717-1.00347-4

90.

Shorr RI (2007) In: Hoth AB, Rawls N (eds) Drugs for the geriatric patient. W.B. Saunders, Philadelphia, pp 115–172. https://doi.org/10.1016/B978-141600208-6.50006-1 CrossRef

91.

Dash AK, Saha S (1996) Mafenide Acetate. In: Brittain HG (ed) Analytical Profiles of Drug Substances and Excipients, vol 24. Academic Press, San Diego, pp 277–305. https://doi.org/10.1016/S0099-5428(08)60696-6

92.

Scholar E (2007) Mafenide. In: Enna SJ, Bylund DB (eds) xPharm: the comprehensive pharmacology reference. Elsevier, New York, pp 1–4. https://doi.org/10.1016/B978-008055232-3.62088-4

93.

Zhang X-J, Heggers JP, Chinkes DL, Wolf SE, Hawkins HK, Wolfe RR (2006) Topical sulfamylon cream inhibits DNA and protein synthesis in the skin donor site wound. Surgery 139(5):633–639. https://doi.org/10.1016/j.surg.2005.10.013 CrossRefPubMed

94.

Cambiaso-Daniel J, Gallagher JJ, Norbury WB, Finnerty CC, Herndon DN, Culnan DM (2018) 11 - Treatment of Infection in Burn Patients. In: Herndon DN (ed) Total burn care (fifth edition). Elsevier, Edinburgh, pp 93–113.e114. https://doi.org/10.1016/B978-0-323-47661-4.00011-3

95.

Marsicano AR Jr, Hutton JJ, Bryant WM (1973) Fatal hemolysis from mafenide treatment of burns in a patient with glucose-6-phosphate dehydrogenase deficiency. Case report. Plast Reconstr Surg 52(2):197–199CrossRef

96.

Mafenide acetate cream: a review (1971) Drugs 1(6):434–460. https://doi.org/10.2165/00003495-197101060-00002

97.

Mafenide (2016) In: Aronson JK (ed) Meyler’s side effects of drugs (Sixteenth Edition). Elsevier, Oxford, p 728. https://doi.org/10.1016/B978-0-444-53717-1.01011-8

98.

Harrison HN, Shuck JM, Caldwell E (1975) Studies of the pain produced by mafenide acetate preparations in burns. Arch Surg 110(12):1446–1449. https://doi.org/10.1001/archsurg.1975.01360180016003 CrossRefPubMed

99.

Lamb YJ (1991) Overview of the role of mupirocin. J Hosp Infect 19:27–30. https://doi.org/10.1016/0195-6701(91)90199-I CrossRefPubMed

100.

van Bambeke F, Mingeot-Leclercq M-P, Glupczynski Y, Tulkens PM (2017) 137 - mechanisms of action. In: Cohen J, Powderly WG, Opal SM (eds) Infectious diseases (fourth edition). Elsevier, pp 1162-1180.e1161. https://doi.org/10.1016/B978-0-7020-6285-8.00137-4

101.

Fraise AP (2010) CHAPTER 23 - mupirocin. In: Finch RG, Greenwood D, Norrby SR, Whitley RJ (eds) Antibiotic and chemotherapy, Ninth edn. Saunders, London, pp 290–291. https://doi.org/10.1016/B978-0-7020-4064-1.00023-3

102.

Balin AK, Leong I, Carter DM (1987) Effect of mupirocin on the growth and lifespan of human fibroblasts. J Invest Dermatol 88(6):736–740. https://doi.org/10.1111/1523-1747.ep12470407 CrossRefPubMed

103.

Gisby J, Bryant J (2000) Efficacy of a new cream formulation of mupirocin: comparison with oral and topical agents in experimental skin infections. Antimicrob Agents Chemother 44(2):255–260CrossRef

104.

Bork K, Brauers J, Kresken M (1989) Efficacy and safety of 2% mupirocin ointment in the treatment of primary and secondary skin infections--an open multicentre trial. Br J Clin Pract 43(8):284–288PubMed

105.

Mupirocin (2016) In: Aronson JK (ed) Meyler’s side effects of drugs (Sixteenth Edition). Elsevier, Oxford, p 1138. https://doi.org/10.1016/B978-0-444-53717-1.01113-6

106.

Herold DA, Rodeheaver GT, Bellamy WT, Fitton LA, Bruns DE, Edlich RF (1982) Toxicity of topical polyethylene glycol. Toxicol Appl Pharmacol 65(2):329–335. https://doi.org/10.1016/0041-008X(82)90016-3 CrossRefPubMed

107.

Mueller RS (2008) Chapter 24 - topical dermatological therapy. In: Maddison JE, Page SW, Church DB (eds) Small animal clinical pharmacology (second edn). Saunders, Edinburgh, pp 546–556. https://doi.org/10.1016/B978-070202858-8.50026-9

108.

Lovering AM, Reeves DS (2011) CHAPTER 12 - Aminoglycosides and aminocyclitols. In: Finch RG, Greenwood D, Norrby SR, Whitley RJ (eds) Antibiotic and chemotherapy (ninth edition). Saunders, London, pp 145–169. https://doi.org/10.1016/B978-0-7020-4064-1.00012-9

109.

Pádua CAMD, Schnuch A, Lessmann H, Geier J, Pfahlberg A, Uter W (2005) Contact allergy to neomycin sulfate: results of a multifactorial analysis. Pharmacoepidemiol Drug Saf 14(10):725–733. https://doi.org/10.1002/pds.1117 CrossRef

110.

Masur H, Whelton PK, Whelton A (1976) Neomycin toxicity revisited. Arch Surg 111(7):822–825CrossRef

111.

Huth ME, Ricci AJ, Cheng AG (2011) Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol 2011:937861. https://doi.org/10.1155/2011/937861 CrossRefPubMedPubMedCentral

112.

Ansari IA, Onyema E (2008) Severe generalised hypersensitivity reaction to topical neomycin after cataract surgery: a case report. J Med Case Rep 2:57–57. https://doi.org/10.1186/1752-1947-2-57 CrossRefPubMedPubMedCentral

113.

Goh CL (1986) Anaphylaxis from topical neomycin and bacitracin. Australas J Dermatol 27(3):125–126CrossRef

114.

Rosen J, Landriscina A, Kutner A, Adler BL, Krausz AE, Nosanchuk JD, Friedman AJ (2015) Silver sulfadiazine retards wound healing in mice via alterations in cytokine expression. J Invest Dermatol 135(5):1459–1462. https://doi.org/10.1038/jid.2015.21 CrossRefPubMed

115.

McCauley RL, Li Y-Y, Poole B, Evans MJ, Robson MC, Heggers JP, Herndon DN (1992) Differential inhibition of human basal keratinocyte growth to silver sulfadiazine and mafenide acetate. J Surg Res 52(3):276–285. https://doi.org/10.1016/0022-4804(92)90086-F CrossRef

116.

Lee A-RC, Moon HK (2003) Effect of topically applied silver sulfadiazine on fibroblast cell proliferation and biomechanical properties of the wound. Arch Pharm Res 26(10):855–860. https://doi.org/10.1007/bf02980032 CrossRefPubMed

117.

Chung DH, Colon NC, Herndon DN (2012) Chapter 26 - Burns. In: Coran AG (ed) Pediatric surgery (Seventh edn). Mosby, Philadelphia, pp 369–384. https://doi.org/10.1016/B978-0-323-07255-7.00026-X

118.

Rowland Payne CE, Bladin C, Colchester AF, Bland J, Lapworth R, Lane D (1992) Argyria from excessive use of topical silver sulphadiazine. Lancet 340(8811):126. https://doi.org/10.1016/0140-6736(92)90458-F CrossRef

119.

Ungureanu M (2014) Concepts in local treatment of extensive paediatric burns. J Med Life 7(2):183–191PubMedPubMedCentral

120.

Wang X-W, Wang NZ, Zhang OZ, Zapata-Sirvent RL, Davies JWL (1985) Tissue deposition of silver following topical use of silver sulphadiazine in extensive burns. Burns 11(3):197–201. https://doi.org/10.1016/0305-4179(85)90070-1 CrossRef

121.

Chaby G, Viseux V, Poulain JF, De Cagny B, Denoeux JP, Lok C (2005) Topical silver sulfadiazine-induced acute renal failure. Ann Dermatol Venereol 132(11 Pt 1):891–893CrossRef

122.

Maitre S, Jaber K, Perrot JL, Guy C, Cambazard F (2002) Increased serum and urinary levels of silver during treatment with topical silver sulfadiazine. Ann Dermatol Venereol 129(2):217–219PubMed

123.

Wan AT, Conyers RA, Coombs CJ, Masterton JP (1991) Determination of silver in blood, urine, and tissues of volunteers and burn patients. Clin Chem 37(10 Pt 1):1683–1687PubMed

124.

Eldad A, Neuman A, Weinberg A, Benmeir P, Rotem M, Wexler MR (1991) Silver sulphadiazine-induced haemolytic anaemia in a glucose-6-phosphate dehydrogenase-deficient burn patient. Burns 17(5):430–432CrossRef

125.

Bardal SK, Waechter JE, Martin DS (2011) Chapter 18 - Infectious diseases. In: Dimock K, Hyde M, Cicalese B (eds) Applied pharmacology. Saunders, Philadelphia, pp 233–291. https://doi.org/10.1016/B978-1-4377-0310-8.00018-X

126.

Gupta SC, Kunnumakkara AB, Aggarwal BB (2017) Chapter 12 - Curcumin, the holistic Avant-Garde. In: Patwardhan B, Chaguturu R (eds) Innovative approaches in drug discovery. Academic Press, Boston, pp 343–349. https://doi.org/10.1016/B978-0-12-801814-9.00012-X

127.

Krausz AE, Adler BL, Cabral V, Navati M, Doerner J, Charafeddine RA, Chandra D, Liang H, Gunther L, Clendaniel A, Harper S, Friedman JM, Nosanchuk JD, Friedman AJ (2015) Curcumin-encapsulated nanoparticles as innovative antimicrobial and wound healing agent. Nanomedicine 11(1):195–206. https://doi.org/10.1016/j.nano.2014.09.004 CrossRefPubMed

128.

Mohanty C, Sahoo SK (2017) Curcumin and its topical formulations for wound healing applications. Drug Discov Today 22(10):1582–1592.https://doi.org/10.1016/j.drudis.2017.07.001

129.

Siviero A, Gallo E, Maggini V, Gori L, Mugelli A, Firenzuoli F, Vannacci A (2015) Curcumin, a golden spice with a low bioavailability. J Herb Med 5(2):57–70. https://doi.org/10.1016/j.hermed.2015.03.001 CrossRef

130.

Rachmawati H, Edityaningrum CA, Mauludin R (2013) Molecular inclusion complex of curcumin–β-cyclodextrin nanoparticle to enhance curcumin skin permeability from hydrophilic matrix gel. AAPS PharmSciTech 14(4):1303–1312. https://doi.org/10.1208/s12249-013-0023-5 CrossRefPubMedPubMedCentral

131.

Thayyullathil F, Chathoth S, Hago A, Patel M, Galadari S (2008) Rapid reactive oxygen species (ROS) generation induced by curcumin leads to caspase-dependent and -independent apoptosis in L929 cells. Free Radic Biol Med 45(10):1403–1412. https://doi.org/10.1016/j.freeradbiomed.2008.08.014 CrossRefPubMed

132.

Kloesch B, Becker T, Dietersdorfer E, Kiener H, Steiner G (2013) Anti-inflammatory and apoptotic effects of the polyphenol curcumin on human fibroblast-like synoviocytes. Int Immunopharmacol 15(2):400–405. https://doi.org/10.1016/j.intimp.2013.01.003 CrossRefPubMed

133.

Chakravarti N, Kadara H, Yoon DJ, Shay JW, Myers JN, Lotan D, Sonenberg N, Lotan R (2010) Differential inhibition of protein translation machinery by curcumin in normal, immortalized, and malignant oral epithelial cells. Cancer Prev Res (Phila) 3(3):331–338. https://doi.org/10.1158/1940-6207.capr-09-0076 CrossRef

134.

Choudhuri T, Pal S, Das T, Sa G (2005) Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 280(20):20059–20068. https://doi.org/10.1074/jbc.M410670200 CrossRefPubMed

135.

Irish J, Blair S, Carter DA (2011) The antibacterial activity of honey derived from Australian flora. PLoS One 6(3):e18229. https://doi.org/10.1371/journal.pone.0018229 CrossRefPubMedPubMedCentral

136.

El Sohaimy SA, Masry SHD, Shehata MG (2015) Physicochemical characteristics of honey from different origins. Ann Agric Sci 60(2):279–287. https://doi.org/10.1016/j.aoas.2015.10.015 CrossRef

137.

Majtan J, Klaudiny J, Bohova J, Kohutova L, Dzurova M, Sediva M, Bartosova M, Majtan V (2012) Methylglyoxal-induced modifications of significant honeybee proteinous components in manuka honey: possible therapeutic implications. Fitoterapia 83(4):671–677. https://doi.org/10.1016/j.fitote.2012.02.002 CrossRefPubMed

138.

Jull A, Walker N, Parag V, Molan P, Rodgers A (2008) Randomized clinical trial of honey-impregnated dressings for venous leg ulcers. Br J Surg 95(2):175–182. https://doi.org/10.1002/bjs.6059 CrossRefPubMed

139.

Simon A, Traynor K, Santos K, Blaser G, Bode U, Molan P (2009) Medical honey for wound care—still the ‘latest resort?’. Evid Based Complement Alternat Med 6(2):165–173. https://doi.org/10.1093/ecam/nem175 CrossRefPubMed

140.

Oryan A, Alemzadeh E, Moshiri A (2016) Biological properties and therapeutic activities of honey in wound healing: a narrative review and meta-analysis. J Tissue Viability 25(2):98–118. https://doi.org/10.1016/j.jtv.2015.12.002 CrossRef

141.

Grigoryan K (2016) Chapter 12 - Safety of honey. In: Prakash V, Martín-Belloso O, Keener L et al. (eds) Regulating safety of traditional and ethnic foods. Academic Press, San Diego, pp 217–246. https://doi.org/10.1016/B978-0-12-800605-4.00012-8

142.

Lansdown AB (2006) Silver in health care: antimicrobial effects and safety in use. Curr Probl Dermatol 33:17–34. https://doi.org/10.1159/000093928 CrossRefPubMed

143.

Rai MK, Deshmukh SD, Ingle AP, Gade AK (2012) Silver nanoparticles: the powerful nanoweapon against multidrug-resistant bacteria. J Appl Microbiol 112(5):841–852. https://doi.org/10.1111/j.1365-2672.2012.05253.x CrossRefPubMed

144.

Rai M, Yadav A, Gade A (2009) Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv 27(1):76–83. https://doi.org/10.1016/j.biotechadv.2008.09.002 CrossRef

145.

Durani P, Leaper D (2008) Povidone-iodine: use in hand disinfection, skin preparation and antiseptic irrigation. Int Wound J 5(3):376–387. https://doi.org/10.1111/j.1742-481X.2007.00405.x CrossRefPubMed

146.

Djordjević VB (2004) Free radicals in cell biology. In: Jeon KW (ed) Int Rev Cytol, vol 237. Academic Press, Amsterdam, pp 57–89. https://doi.org/10.1016/S0074-7696(04)37002-6

147.

McDonnell G (2009) The use of hydrogen peroxide for disinfection and sterilization applications. In: Marek I (ed) PATAI’S chemistry of functional groups. Wiley, New York. https://doi.org/10.1002/9780470682531.pat0885

148.

Greenwood D (2010) CHAPTER 31 - Miscellaneous antibacterial agents. In: Finch RG, Greenwood D, Norrby SR, Whitley RJ (eds) Antibiotic and chemotherapy (Ninth edn). Saunders, London, pp 356–365. https://doi.org/10.1016/B978-0-7020-4064-1.00031-2

149.

Lee VJ (2007) 7.22 - Anti-gram positive agents of natural product origins. In: Taylor JB, Triggle DJ (eds) Comprehensive medicinal chemistry II. Elsevier, Oxford, pp 653–671. https://doi.org/10.1016/B0-08-045044-X/00222-4

150.

Kester M, Karpa KD, Vrana KE (2012) 4 - Treatment of infectious diseases. In: Hyde M, Hall A (eds) Elsevier’s integrated review pharmacology (second edn). W.B. Saunders, Philadelphia, pp 41–78. https://doi.org/10.1016/B978-0-323-07445-2.00004-5

151.

Heyneman A, Hoeksema H, Vandekerckhove D, Pirayesh A, Monstrey S (2016) The role of silver sulphadiazine in the conservative treatment of partial thickness burn wounds: a systematic review. Burns 42(7):1377–1386. https://doi.org/10.1016/j.burns.2016.03.029 CrossRefPubMed

152.

Carr HS, Wlodkowski TJ, Rosenkranz HS (1973) Silver sulfadiazine: in vitro antibacterial activity. Antimicrob Agents Chemother 4(5):585–587CrossRef

153.

Rai D, Singh JK, Roy N, Panda D (2008) Curcumin inhibits FtsZ assembly: an attractive mechanism for its antibacterial activity. Biochem J 410(1):147–155. https://doi.org/10.1042/bj20070891 CrossRefPubMed

154.

Yun DG, Lee DG (2016) Antibacterial activity of curcumin via apoptosis-like response in Escherichia coli. Appl Microbiol Biotechnol 100(12):5505–5514. https://doi.org/10.1007/s00253-016-7415-x CrossRefPubMed

155.

Tyagi P, Singh M, Kumari H, Kumari A, Mukhopadhyay K (2015) Bactericidal activity of curcumin I is associated with damaging of bacterial membrane. PLoS One 10(3):e0121313. https://doi.org/10.1371/journal.pone.0121313 CrossRefPubMedPubMedCentral

156.

Moghadamtousi SZ, Kadir HA, Hassandarvish P, Tajik H, Abubakar S, Zandi K (2014) A review on antibacterial, antiviral, and antifungal activity of curcumin. Biomed Res Int 2014:186864. https://doi.org/10.1155/2014/186864 CrossRefPubMed

157.

Mandal MD, Mandal S (2011) Honey: its medicinal property and antibacterial activity. Asian Pac J Trop Biomed 1(2):154–160. https://doi.org/10.1016/S2221-1691(11)60016-6 CrossRefPubMedPubMedCentral

158.

Wound dressings (2016) In: Aronson JK (ed) Meyler’s side effects of drugs (Sixteenth edn). Elsevier, Oxford, pp 525–526. https://doi.org/10.1016/B978-0-444-53717-1.01644-9

159.

Tamma PD, Aucott SW, Milstone AM (2010) Chlorhexidine use in the neonatal intensive care unit: results from a national survey. Infect Control Hosp Epidemiol 31(8):846–849. https://doi.org/10.1086/655017 CrossRefPubMedPubMedCentral

160.

Chapman AK, Aucott SW, Gilmore MM, Advani S, Clarke W, Milstone AM (2013) Absorption and tolerability of aqueous chlorhexidine gluconate used for skin antisepsis prior to catheter insertion in preterm neonates. J Perinatol 33(10):768–771. https://doi.org/10.1038/jp.2013.61 CrossRefPubMedPubMedCentral

161.

Shah AR, Liao LF (2017) Pediatric burn care: Unique Considerations in Management. Clin Plast Surg 44(3):603–610. https://doi.org/10.1016/j.cps.2017.02.017 CrossRefPubMed

Title: The downside of antimicrobial agents for wound healing
Authors: Apirujee Punjataewakupt
Supamas Napavichayanun
Pornanong Aramwit
Publication date: 01-01-2019
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 1/2019
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-018-3393-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The downside of antimicrobial agents for wound healing

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Single-center analysis of infectious complications in older adults during the first year after kidney transplantation

Performance of rapid antimicrobial susceptibility testing by disk diffusion on MHR-SIR agar directly on urine specimens

Differences in mortality in Fusobacterium necrophorum and Fusobacterium nucleatum infections detected by culture and 16S rRNA gene sequencing

Diagnostic methods for Helicobacter pylori infection: ideals, options, and limitations

Evaluation of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for identifying Burkholderia pseudomallei and Burkholderia thailandensis isolates

From dengue to Zika: the wide spread of mosquito-borne arboviruses

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page